Infection and Immunity · 1991 · 64 citations · 27 references
Veterinary MedicineImmunologyAdaptive ImmunityImmunizationVaccinologyImmune Response To VaccinationProtective ImmunitySubunit VaccinesVaccinationVaccine-preventable DiseasesViral VaccinesAnimal ImmunizationAnthrax VaccinesGuinea Pig ModelsProtective Antibody TitersProtective Antigen IdentificationProtective AntigensRecombinant Antigen ExpressionViral Vector Immunogenicity
We previously described the cloning and expression of the protective antigen (PA) gene of Bacillus anthracis in both vaccinia virus and a baculovirus. The antigenicity of the PA products was characterized. PA expressed by the recombinant vaccinia viruses elicited a partial protective immune response against a lethal B. anthracis spore challenge in guinea pigs and mice. The WR strain vaccinia virus recombinant (WR-PA) protected 60% of male mice and 50% of guinea pigs. WR-PA elicited high anti-PA antibody titers in mice but not in guinea pigs. Connaught strain vaccinia virus recombinants failed to protect any immunized animals. PA purified from baculovirus recombinant-infected cultures plus adjuvant partially protected male CBA/J mice and completely protected female Hartley guinea pigs from challenge. Both the recombinant and nonrecombinant PA preparations combined with adjuvant elicited high anti-PA antibody titers in Hartley guinea pigs and CBA/J mice. These data demonstrate that the recombinant baculovirus- and vaccinia virus-produced PAs were immunogenic in both guinea pigs and mice, that the baculovirus-PA recombinant was a useful source of immunogenic PA, and that vaccinia virus-PA recombinants may be feasible live anthrax vaccine candidates worthy of consideration for further development as live vaccines.
27
A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures.
Summers, Gale Smith · 1987 · 1.7K citations